{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:03:14Z","timestamp":1782846194060,"version":"3.54.5"},"reference-count":53,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Antipsychotic-induced weight gain is a common side effect of antipsychotic drug treatment, particularly with second-generation medications such as clozapine and olanzapine. Weight gain in patients undergoing antipsychotic therapies is a significant concern, often compounded by factors related to their condition that can be particularly challenging in a secure care setting. While there is significant evidence to support the benefits of semaglutide, one of the available glucagon-like peptide-1 receptor agonists, in promoting weight loss for those who have a general weight-related health issue and meet the referral criteria for specialist services, it is unclear whether it will be as successful in people who have specifically gained weight due to medication-associated side effects and who reside in a secure care setting.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study aims to assess the impact of semaglutide in combination with a lifestyle behavior change intervention on the physical health measures of patients in a secure setting who have atypical antipsychotic\u2013induced weight gain and identify enhancements to the intervention, specifically geared toward improving adherence and acceptability from both staff and patient perspectives.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This 2-year uncontrolled pretest-posttest pilot study aims to recruit 20 inpatient participants. Adult patients of any diabetic status with a minimum BMI of 35.0 kg\/m\n 2<\/jats:sup>\n (or a BMI of 32.5 kg\/m\n 2<\/jats:sup>\n for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean descent) who are receiving inpatient treatment and are treated with either olanzapine or clozapine will be eligible for inclusion in the study. Patients will receive semaglutide (Wegovy) at a maintenance dose of 2.4 mg once a week for 2 years. All participants will also receive a lifestyle behavior change intervention.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The findings will reveal whether the format of the interventional approach is both sustainable and effective for adult patients diagnosed with severe mental illness and living with obesity who are currently residing in a secure mental health setting. Implementation changes that could improve the acceptability of and adherence to the intervention will be explored.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This research should be beneficial for patients with severe mental illness who are living with obesity and are residing in a secure setting as the findings may ultimately reduce the mortality risk in this patient group.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/76013","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T19:22:05Z","timestamp":1765308125000},"page":"e76013-e76013","source":"Crossref","is-referenced-by-count":1,"title":["The Effect of Semaglutide With Lifestyle Intervention on the Physical Health of Patients Treated With Antipsychotic Drugs in a Secure Mental Health Setting: Protocol for an Uncontrolled Pretest-Posttest Pilot Mixed Methods Study"],"prefix":"10.2196","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3512-5535","authenticated-orcid":false,"given":"Kristina","family":"Brenisin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3095-7116","authenticated-orcid":false,"given":"Florence","family":"Kinnafick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8174-9173","authenticated-orcid":false,"given":"James","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0787-1763","authenticated-orcid":false,"given":"Louise","family":"Millard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1839-3033","authenticated-orcid":false,"given":"Donna","family":"Arya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2935-7326","authenticated-orcid":false,"given":"Elizabeth","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8293-9289","authenticated-orcid":false,"given":"Michelle","family":"Huggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9789-2664","authenticated-orcid":false,"given":"Andrew","family":"Simmons-Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8351-9362","authenticated-orcid":false,"given":"Martin","family":"O'Dowd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5688-5405","authenticated-orcid":false,"given":"Nick","family":"Rayment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5779-2271","authenticated-orcid":false,"given":"Parul","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3974-4237","authenticated-orcid":false,"given":"Kieran C","family":"Breen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"issue":"1","key":"R1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12888-019-2274-5","article-title":"\u201cWalk this way\u201d: results from a pilot randomised controlled trial of a health coaching intervention to reduce sedentary behaviour and increase physical activity in people with serious mental illness","volume":"19","author":"Williams","journal-title":"BMC Psychiatry"},{"issue":"2","key":"R2","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/healthcare2020166","article-title":"Obesity and serious mental ill health: a critical review of the literature","volume":"2","author":"Bradshaw","journal-title":"Healthcare (Basel)"},{"issue":"1","key":"R3","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12888-018-1878-5","article-title":"Long-term psychiatric inpatients\u2019 perspectives on weight gain, body satisfaction, diet and physical activity: a mixed methods study","volume":"18","author":"Every-Palmer","journal-title":"BMC Psychiatry"},{"issue":"2","key":"R4","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(21)00500-9","article-title":"Psychotropic medicines: increased appetite rather than weight gain","volume":"9","author":"Tondo","journal-title":"Lancet Psychiatry"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-020-00292-5","article-title":"The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey","volume":"19","author":"Tandon","journal-title":"Ann Gen Psychiatry"},{"issue":"26","key":"R6","doi-asserted-by":"publisher","first-page":"3732","DOI":"10.2174\/1381612821666150605111236","article-title":"Atypical antipsychotics and inverse agonism at 5-HT2 receptors","volume":"21","author":"Sullivan","journal-title":"Curr Pharm Des"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S113099","article-title":"Antipsychotic-associated weight gain: management strategies and impact on treatment adherence","volume":"13","author":"Dayabandara","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"R8","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1177\/0148607108321708","article-title":"Drug-induced hyperphagia: what can we learn from psychiatric medications?","volume":"32","author":"Jensen","journal-title":"JPEN J Parenter Enteral Nutr"},{"issue":"9896","key":"R9","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","journal-title":"Lancet"},{"issue":"10","key":"R10","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","article-title":"Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors","volume":"174","author":"Leucht","journal-title":"Am J Psychiatry"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.573479","article-title":"Impact of psychotropic medication effects on obesity and the metabolic syndrome in people with serious mental illness","volume":"11","author":"Mazereel","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"R12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","journal-title":"Lancet Psychiatry"},{"issue":"6","key":"R13","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/oby.22794","article-title":"Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5","volume":"28","author":"Kushner","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"R14","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1017\/S0007114522003403","article-title":"Weight management interventions for adults living with overweight or obesity and severe mental illness: a systematic review and meta-analysis","volume":"130","author":"Stevens","journal-title":"Br J Nutr"},{"issue":"3","key":"R15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/wps.20666","article-title":"Toward a personalized approach to psychotherapy outcome and the study of therapeutic change","volume":"18","author":"Barber","journal-title":"World Psychiatry"},{"issue":"9","key":"R16","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1001\/jamapsychiatry.2023.1566","article-title":"Effectiveness of a lifestyle intervention for people with a severe mental illness in Dutch outpatient mental health care: a randomized clinical trial","volume":"80","author":"Walburg","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"R17","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1177\/0004867415590831","article-title":"Integrating physical activity as medicine in the care of people with severe mental illness","volume":"49","author":"Vancampfort","journal-title":"Aust N Z J Psychiatry"},{"issue":"7","key":"R18","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1177\/13591053241227384","article-title":"Effectiveness of lifestyle intervention on prevention\/management of antipsychotic-induced weight gain among persons with severe mental illness: a systematic review and meta-analysis","volume":"29","author":"Mohanty","journal-title":"J Health Psychol"},{"issue":"17","key":"R19","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s40265-020-01393-x","article-title":"Pharmacological management of glucose dysregulation in patients treated with second-generation antipsychotics","volume":"80","author":"Cernea","journal-title":"Drugs"},{"issue":"4","key":"R20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015861","article-title":"Pharmacological treatments for adults with overweight and obesity without diabetes","volume":"2024","author":"Shang","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"R21","volume":"87","author":"Stogios","journal-title":"Biol Psychiatry"},{"issue":"1","key":"R22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/wps.20614","article-title":"The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials","volume":"18","author":"Vancampfort","journal-title":"World Psychiatry"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-072686","article-title":"Effectiveness and safety of drugs for obesity","volume":"384","author":"Henderson Lewis","journal-title":"BMJ"},{"issue":"2","key":"R24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/dom.13522","article-title":"Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis","volume":"21","author":"Siskind","journal-title":"Diabetes Obes Metab"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.2007.s434","article-title":"The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion","volume":"51 Suppl 3","author":"MacDonald","journal-title":"Diabetes"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","journal-title":"Mol Metab"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R28","unstructured":"Semaglutide for managing overweight and obesity. National Institute for Health and Care Excellence. 2023. URL: https:\/\/www.nice.org.uk\/guidance\/ta875\/resources\/semaglutide-for-managing-overweight-and-obesity-pdf-82613674831813 [Accessed 29-11-2025]"},{"issue":"6","key":"R29","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1007\/s12325-022-02153-x","article-title":"Efficacy of GLP-1 RA approved for weight management in patients with or without diabetes: a narrative review","volume":"39","author":"Jensterle","journal-title":"Adv Ther"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2024.04.041","article-title":"Long-term efficacy and safety of once-weekly semaglutide for weight loss in patients without diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"222","author":"Moiz","journal-title":"Am J Cardiol"},{"issue":"11","key":"R31","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","journal-title":"N Engl J Med"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S365416","article-title":"Clinical insight on semaglutide for chronic weight management in adults: patient selection and special considerations","volume":"16","author":"Chao","journal-title":"Drug Des Devel Ther"},{"issue":"10","key":"R33","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","journal-title":"Nat Med"},{"issue":"24","key":"R34","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","journal-title":"N Engl J Med"},{"issue":"9","key":"R35","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"R36","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","journal-title":"Nat Med"},{"issue":"6","key":"R37","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/acps.13734","article-title":"Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: a systematic review and meta-analysis","volume":"150","author":"Bak","journal-title":"Acta Psychiatr Scand"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1177\/20451253231165169","article-title":"Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series","volume":"13","author":"Prasad","journal-title":"Ther Adv Psychopharmacol"},{"issue":"1","key":"R39","doi-asserted-by":"publisher","first-page":"e068652","DOI":"10.1136\/bmjopen-2022-068652","article-title":"Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)","volume":"13","author":"Sass","journal-title":"BMJ Open"},{"issue":"4","key":"R40","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1192\/bjo.2023.532","article-title":"Effects of semaglutide on body weight in clozapine-treated people with schizophrenia and obesity: study protocol for a placebo-controlled, randomised multicentre trial (COaST)","volume":"9","author":"Siskind","journal-title":"BJPsych Open"},{"issue":"6","key":"R41","doi-asserted-by":"publisher","first-page":"e13435","DOI":"10.1111\/obr.13435","article-title":"Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials","volume":"23","author":"Iqbal","journal-title":"Obes Rev"},{"issue":"6","key":"R42","doi-asserted-by":"publisher","first-page":"205141581772471","DOI":"10.1177\/2051415817724713","article-title":"Gathering preliminary data","volume":"10","author":"Winchester","journal-title":"J Clin Urol"},{"issue":"12","key":"R43","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/ejcn.2015.57","article-title":"Preliminary validation and principal components analysis of the Control of Eating Questionnaire (CoEQ) for the experience of food craving","volume":"69","author":"Dalton","journal-title":"Eur J Clin Nutr"},{"issue":"1","key":"R44","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.appet.2007.06.007","article-title":"The role of implicit wanting in relation to explicit liking and wanting for food: implications for appetite control","volume":"50","author":"Finlayson","journal-title":"Appetite"},{"issue":"3","key":"R45","doi-asserted-by":"publisher","first-page":"e12310","DOI":"10.1111\/cob.12310","article-title":"Validation of a new measure of quality of life in obesity trials: impact of weight on quality of life-lite clinical trials version","volume":"9","author":"Kolotkin","journal-title":"Clin Obes"},{"issue":"4","key":"R46","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/14707853231222139","article-title":"Diary studies in research: more than a research method","volume":"66","author":"Olorunfemi","journal-title":"Int J Market Res"},{"key":"R47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2021.104163","article-title":"Wearable technology-delivered lifestyle intervention amongst adults with overweight and obese: a systematic review and meta-regression","volume":"127","author":"Wong","journal-title":"Int J Nurs Stud"},{"issue":"4","key":"R48","volume":"72","author":"Srivastava","journal-title":"J Admin Govern"},{"issue":"10","key":"R49","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1111\/dom.15802","article-title":"Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: a randomized controlled trial","volume":"26","author":"Gabe","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"R50","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s11154-021-09699-1","article-title":"Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes","volume":"23","author":"Mahapatra","journal-title":"Rev Endocr Metab Disord"},{"key":"R51","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117179","article-title":"Advances in small-molecule insulin secretagogues for diabetes treatment","volume":"178","author":"Su","journal-title":"Biomed Pharmacother"},{"issue":"S1","key":"R52","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/2327-6924.12510","article-title":"Obesity: risk factors, complications, and strategies for sustainable long-term weight management","volume":"29","author":"Fruh","journal-title":"J Am Assoc Nurse Pract"},{"issue":"7","key":"R53","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1002\/oby.24042","article-title":"Efficacy and safety of semaglutide 2.4\u2009mg by race and ethnicity: a post hoc analysis of three randomized controlled trials","volume":"32","author":"Rubino","journal-title":"Obesity (Silver Spring)"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2025\/1\/e76013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:07:24Z","timestamp":1782842844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2025\/1\/e76013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":53,"URL":"https:\/\/doi.org\/10.2196\/76013","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"article-number":"v14i1e76013"}}